Recent therapeutic advances in IO include the use of check-point-inhibitors, bispecific antibodies and cellular therapeutics within the clinic. Our assays are designed to test single and combinatorial therapy using all therapeutic modalities. Assays cover key mechanisms such as ADCC, NK and CD8 cytotoxicity

Current drive is to find more targeted therapeutics rather than global immunosuppressants. Key assays are designed to test both small molecules and biologics such as cytokine neutralising antibodies, against the major drivers of autoimmunity including CD4 T cells, B cells and antigen presenting cells.

Uncontrolled inflammation that causes tissue damage has driven the need for targeted immuno-modulators. There are multiple players in the inflammatory processes that can be modelled in vitro including standard cytokine release and inflammasome assays or more customised multicellular assays.